Novavax | NVAX - Current Liabilities

Stock Price
8.45
Daily Change
-0.50 -5.59%
Monthly
-16.42%
Yearly
20.71%
Q1 Forecast
9.06

Novavax reported $459.95M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Adma Biologics USD 69.54M 13.05M Dec/2025
Agenus USD 323.49M 36.36M Dec/2025
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 196.07M 5.83M Dec/2025
Cassava Sciences USD 43.83M 4.21M Dec/2025
Geron USD 113.82M 26.11M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
MannKind USD 171.03M 61.9M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.29M 381K Dec/2025
Moderna USD 1.99B 306M Dec/2025
Novartis USD 27.28B 4.72B Dec/2025
Novavax USD 459.95M 30.08M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
TG Therapeutics USD 153.76M 3.05M Dec/2025